Medical device company with a QuantaFlo product for detecting Peripheral Artery Disease (PDA). The product is easier to use and lower cost compared to other PDA testing methodologies. Studies have shown that QuantaFlo is at least as good as other testing alternatives. The upside is based on continued gradual penetration increase and revenue growth. PDA is a chronic disease that so far goes undetected in c. 30% of a given doctor’s older population. Bearish concerns of QuantaFlo being to-good-to-be-true or regarding lack of clarity if insurers will compensate testing are overly exaggerated.